Inhibitors in coagulation are acquired antibodies that act by either neutralizing or inhibiting the activity of specific clotting factors or, alternatively, enhancing their degradation and clearance . Clinically, these occur in two pathogenetically distinct scenarios. The first is when these antibodies occur idiopathically, or in association with other disorders like malignancies, pregnancy, drug exposures, or systemic autoimmune disorders. Such autoantibodies (“auto” since they are directed against the affected individual’s own antigens) usually result in a bleeding diathesis as their most common clinical manifestation. Antiphospholipid antibodies (APLA) are a special subset of this group, since their unique properties cause thromboses more often than abnormal bleeding .
KeywordsAcquired hemophilia Antiphosphoplipid antibodies Bleeding Coagulation Hemostatic disorders Inhibitors Thrombosis
- 2.Giangrande P. Acquired hemophilia. Monograph published by the World Federation of Hemophilia (WFH) 2005, revised 2012. No. 38; Nov 2012. www.wfh.org/publication/files/pdf-1186.pdf. Accessed 31 Jul 2018.
- 4.Bain BJ, Bates I, Laffan MA, Lewis SM. Dacie and lewis’ practical haematology. 12/e; 2017.Google Scholar
- 13.Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76(10):1637–41.CrossRefGoogle Scholar
- 14.Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295.CrossRefGoogle Scholar
- 15.Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737–40.CrossRefGoogle Scholar
- 18.Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefGoogle Scholar
- 19.Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, Rowell J, Smith M, Tran H, Hematology Working Group. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. Intern Med J. 2012;42(11):1243–50.CrossRefGoogle Scholar
- 27.Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost. 2015;113(5):958–67.CrossRefGoogle Scholar